David C. Linch
Impact in
- Hematology top 0.02%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
- Virus-based gene therapy research
Papers in
- Hematology 176
- Acute Myeloid Leukemia Research 87
- Hematopoietic Stem Cell Transplantation 74
- Genetics 103
- Chronic Lymphocytic Leukemia Research 46
- Myeloproliferative Neoplasms: Diagnosis and Treatment 35
- Co-authors
- Rosemary E. Gale (89 shared papers)Alan K. Burnett (29 shared papers)Robert K. Hills (36 shared papers)Anthony H. Goldstone (53 shared papers)Panagiotis D. Kottaridis (19 shared papers)Anthony H. Goldstone (20 shared papers)Asim Ijaz Khwaja (28 shared papers)Rajesh Kumar Chopra (15 shared papers)
- Journals
- British Journal of Haematology (111 papers)Blood (95 papers)Journal of Clinical Oncology (24 papers)The Lancet (18 papers)Leukemia (8 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
David C. Linch
414 papers receiving 28.4k citations
David C. Linch's Hit Papers
Peers
Comparison fields: 5 of 155
- Hematology 11.7k
- Genetics 5.5k
- Pathology and Forensic Medicine 7.4k
- Oncology 8.2k
- Immunology 4.3k
Countries citing papers authored by David C. Linch
This map shows the geographic impact of David C. Linch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Linch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Linch more than expected).
Fields of papers citing papers by David C. Linch
This network shows the impact of papers produced by David C. Linch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Linch. The network helps show where David C. Linch may publish in the future.
Co-authors
The 25 scholars most cited alongside David C. Linch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 421 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B Hit paper breakdown → | 2011 | 1544 |
| 2 | Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era Hit paper breakdown → | 2010 | 1349 |
| 3 | The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Hit paper breakdown → | 2001 | 1328 |
| 4 | Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients Hit paper breakdown → | 2008 | 1055 |
| 5 | Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial Hit paper breakdown → | 1993 | 886 |
| 6 | Assessment of Minimal Residual Disease in Standard-Risk AML Hit paper breakdown → | 2016 | 691 |
| 7 | The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia Hit paper breakdown → | 2007 | 640 |
| 8 | 1996 | 510 | |
| 9 | 2000 | 456 | |
| 10 | Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles Hit paper breakdown → | 2013 | 446 |
| 11 | 2000 | 387 | |
| 12 | 1984 | 368 | |
| 13 | 2007 | 363 | |
| 14 | 2014 | 346 | |
| 15 | 2016 | 335 | |
| 16 | 2002 | 324 | |
| 17 | 2002 | 309 | |
| 18 | 2014 | 300 | |
| 19 | 2011 | 288 | |
| 20 | 2002 | 272 |
About David C. Linch
David C. Linch is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Oncology and Immunology, having authored 421 papers that have together received 29.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (119 papers), Acute Myeloid Leukemia Research (87 papers), Hematopoietic Stem Cell Transplantation (74 papers), Chronic Lymphocytic Leukemia Research (46 papers), Acute Lymphoblastic Leukemia research (44 papers), Viral-associated cancers and disorders (38 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (35 papers) and CAR-T cell therapy research (29 papers). The work is most often cited by research in Hematology (11.7k citations), Genetics (5.5k citations), Pathology and Forensic Medicine (7.4k citations), Oncology (8.2k citations) and Immunology (4.3k citations). David C. Linch has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Rosemary E. Gale, Alan K. Burnett, Robert K. Hills, Anthony H. Goldstone, Panagiotis D. Kottaridis, Anthony H. Goldstone, Asim Ijaz Khwaja, Rajesh Kumar Chopra, Barry W. Hancock and David Cunningham. Their work appears in journals such as British Journal of Haematology, Blood, Journal of Clinical Oncology, The Lancet and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.